Hypothyroidism and AMH in Iraqi Patients with Chronic Kidney Disease

Main Article Content

Noori M. Luaibi
Athraa K. Falhi
Ali J. Alsaedi

Abstract

This study was conducted to investigate thyroid function and Anti-Müllerian hormone (AMH) in (Chronic kidney disease) CKD patients by evaluating their levels in CKD patients, 50 patients were diagnosed to have CKD stage-5, their ages ranged between 20-50 years (25 males and 25 females) who attended the Nephrology and Transplant Center in Medical City of Baghdad- Iraq, they were recruited from April 2018 to July 2018 and were enrolled into the study. The control group consisted of 20 healthy individuals, their ages ranged between 20-48 years (10 males and 10 females). The study showed non-significant (p>0.05) increase in AMH level in CKD patients compared to the control group. On the other hand, TSH was recorded a highly significant (P<0.01) increase in CKD patients in comparison with control. While T3 and T4 levels recorded highly significant (P<0.01) decrease in CKD patients in comparison with control.


 

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Luaibi NM, Falhi AK, Alsaedi AJ. Hypothyroidism and AMH in Iraqi Patients with Chronic Kidney Disease. Baghdad Sci.J [Internet]. 2021Mar.30 [cited 2021Dec.4];18(1(Suppl.):0695. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3681
Section
article

References

Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006 Aug; 17(8): 2275-2284.

Emanuele Di, John D, Gudny E. Vilmundur G. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med. 2007 Sep ; 4 (9): 270.

Lysaght, M J. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol, (2002); 13(1): 37-40.

Dor A, Pauly MV, Eichleay MA, Held PJ. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ. 2007 Sep; 7(2-3): 73-111.

Edey MM. Male Sexual Dysfunction and Chronic Kidney Disease. Front. Med. 2017 Mar; 4(32): 1-10.

Shibusawa K, Saito S, Nishi K, Yamamoto T, Abe C, Kawai T. Effects of the thyrotrophin releasing principle (TRF) after the section of the pituitary stalk. Endocrinol Jpn .1956 ; 3(3): 151-157.

Schweizer U, Weitzel JM, Schomburg L. Think globally: act locally. New insights into the local regulation of thyroid hormone availability challenge long accepted dogmas. Mol Cell Endocrinol. 2008; 289(1-2): 1-28.

Ritchie M, Yeap BB. Thyroid hormone: Influences on mood and cognition in adults. Maturitas. 2015 Jun; 81(2): 266-275.

Iglesias P, Carrero JJ, Díez JJ. Gonadal dysfunction men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 2012 Feb; 25(1): 31-42.

Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum. Reprod Update. 2015 Nov-Dec; 21(6): 698-710.

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-mullerian hormone in women. Hum. Reprod Update. 2014 May-Jun; 20(3): 370-385.

Lindhardt JM, Hagen CP, Johannsen TH, Main KM, Picard JY. AntiMullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013 Dec; 2013: 1-10.

Goulis DG, Iliadou PK, Tsametis C, Gerou S, Tarlatzis BC, Bontis IN, Papadimas et al. Serum anti-Mullerian hormone levels differentiate control from subfertile men but not men with different causes of subfertility. Gynecol Endocrinol. 2008 Mar; 24(3):158-160.

Sikora-Grabkaa E, Adamczaka M, Kuczeraa P, Szotowskaa M, Madejb P, Wieceka A. Serum Anti-Müllerian Hormone Concentration in Young Women with Chronic Kidney Disease on Hemodialysis, and After Successful Kidney Transplantation. Kidney Blood Press Res. 2016 Aug; 2016(41):552-560.

Stoumpos S, Lees J, Welsh P, Hund M, Geddes C, Nelson S, et al. The utility of anti-Müllerian hormone in women with chronic kidney disease, on haemodialysis and after kidney transplantation. Reprod Biomed Online. 2018 Feb; 36 (2):219-226.

Eckersten D, Giwercman A, Bruun L, Christensson A. Anti-Mullerian hormone, a Sertoli cell-derived marker, is decreased in plasma of male patients in all stages of chronic kidney disease. Androl. 2015 Oct; 3(6): 1160-1164.

Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol, 2012 Jul; 23 (7): 1258-1270.

Eckersten D, Giwercman A, Christensson A. Male patients with terminal renal failure exhibit low serum levels of antimüllerian hormone. Asian J Androl. 2015b Jan-Feb; 17(1): 149-153

Singh Sm, Verma A, Aryal A, Thapa S, Khakurel S, Shrestha K. Thyroid hormone profile in patients with chronic kidney disease: a single centre study .J Nepal Health Res Counc. 2016 Sep; 14(34): 197-201.

Keerthana BL, Kumar TA. Study of Thyroid and Lipid Profile in Chronic Kidney Disease. Int J Med Health Res. 2016 Mar 2(3): 6-9

Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H. Low triiodothyronine alters flow mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol. 2011Jan; 33(1):25-32.

Thalquotra M, Pandey R, Singh J, Agrawal BK, Sodhi KS. Evaluation of thyroid profile in patients with chronic kidney disease. J Pharm Biomed Sci. 2014 ; 4(2):143-147.

Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS. The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant. 2009 May; 24(5): 1534-1538.

Rajeev G, Chickballapur RW, Vijayalakshmi R, Swathi M, Kumar S. Evaluation of thyroid hormone levels in chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2015 Jan; 26(1): 90-93.

Kannan A, Sriramakrishnan V, Kannan B, Anandan H. Thyroid Function Abnormalities in Patients with Chronic Kidney Disease - A Prospective Study. Int J Sci Study. 2017 Jul; 5(4): 68-72.

Rajagopalan B, Dolia PB, Arumalla VK. Renal function markers and thyroid hormone status in undialyzed chronic kidney disease. Al Ameen J Med Sci. 2013 Jan; 6(1): 70-74.

Kuczera P, Adamczak M, Wiecek A. Endocrine abnormalities in patients with chronic kidney diseases. Sec. of Med. Sci.2015 (36); 2: 109-118.

Khaled MD, Faiz AT, Abdelgader A, Bioprabhu S. Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases of Libya. J Dent Med Sci. 2015; 14(11): 73-81.

Swaminathan K, Rajesh S, Avudaiappan S. A Study of Thyroid Function Abnormalities in Patients with Chronic Kidney Disease. J Dent Med Sci. 2016; 15(8): 7-15.

Kuroda K, Uchida T, Nagai S. Elevated serum thyroid-stimulating hormone is associated with decreased anti-Müllerian hormone in infertile women of reproductive age. J Assist Reprod Genet. 2014 Feb; 32(2): 243-247.

Zhang C, Wang X, Wang Z, Niu W, Zhu B, Xia G. Effect of different culture systems and 3, 5, 3 ′-triiodothyronine/follicle-stimulating hormone on preantral follicle development in mice. PLoS ONE. 2013 Apr; 8(4): 1-7.

Fedail JS, Zheng K, Wei Q, Kong L, Shi F. Roles of thyroid hormones in follicular development in the ovary of neonatal and immature rats. Endocrine. 2014 Aug: 46 (3):594-604.